Xuelin Huang

M. Konopleva, H. Kantarjian, Xuelin Huang, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis

D. Berry, C. Hourigan, Xuelin Huang, 2022, Leukemia.

Clofarabine combinations as acute myeloid leukemia salvage therapy

Z. Estrov, H. Kantarjian, S. Verstovsek, 2008, Cancer.

Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial.

G. Garcia-Manero, Xuelin Huang, K. Patel, 2022, The Lancet. Haematology.

A flexible-hazards cure model with application to patients with soft tissue sarcoma.

P. Pisters, Xuelin Huang, Ruosha Li, 2022, Statistics in medicine.

Estimating treatment effects in observational studies with both prevalent and incident cohorts

Yu Shen, Xuelin Huang, J. Ning, 2017, The Canadian journal of statistics = Revue canadienne de statistique.

Survivin is highly expressed in CD34 (cid:1) 38 (cid:2) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML

K. Coombes, G. Mills, Nianxiang Zhang, 2012 .

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.

K. Rezvani, G. Garcia-Manero, Xuelin Huang, 2022, The Lancet. Haematology.

Clofarabine Plus Anthracycline Combinations in Acute Myeloid Leukemia (AML) Salvage.

Z. Estrov, M. Andreeff, H. Kantarjian, 2006 .

Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

Statistical analysis of clustered mixed recurrent-event data with application to a cancer survivor study

L. Robison, Xuelin Huang, Yimei Li, 2020, Lifetime Data Analysis.

Application of machine learning methods in clinical trials for precision medicine

Xuelin Huang, B. Carter, Ziyi Li, 2021, bioRxiv.

Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.

D. Berry, H. Kantarjian, Shouhao Zhou, 2020, JAMA oncology.

Joint model for a diagnostic test without a gold standard in the presence of a dependent terminal event

Min Yi, Xuelin Huang, Stacia M DeSantis, 2014, Statistics in medicine.

A Bayesian model for misclassified binary outcomes and correlated survival data with applications to breast cancer

Sheng Luo, Min Yi, Xuelin Huang, 2013, Statistics in medicine.

Estimation of the Causal Effects on Survival of Two‐Stage Nonrandomized Treatment Sequences for Recurrent Diseases

P. Pisters, Xuelin Huang, J. Cormier, 2006, Biometrics.

A Bayesian Simulation Model for Breast Cancer Screening, Incidence, Treatment, and Mortality

D. Berry, Xuelin Huang, Yisheng Li, 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

A SIGNATURE ENRICHMENT DESIGN WITH BAYESIAN ADAPTIVE RANDOMIZATION FOR CANCER CLINICAL TRIALS

Fang Xia, S. George, Xuelin Huang, 2019 .

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

H. Kantarjian, J. Cortes, Xuelin Huang, 2012, Cancer.

Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies

Oguzhan Alagoz, Karla Kerlikowske, Xuelin Huang, 2016, Annals of Internal Medicine.

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

J. Issa, Y. Oki, Z. Estrov, 2007, Blood.

CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia.

A. Rosenwald, D. Neuberg, L. Rassenti, 2011, Blood.

Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

K. Baggerly, E. Estey, M. Konopleva, 2014, Clinical Cancer Research.

p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.

M. Konopleva, M. Andreeff, E. Shpall, 2011, Blood.

Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2021, British journal of haematology.

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2020, Leukemia.

Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML.

K. Coombes, G. Mills, Nianxiang Zhang, 2012, Blood.

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.

D. Berry, E. Estey, Yi Guo, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pre-leukemic clonal hematopoiesis and the risk of therapy-related myeloid neoplasms: a case-control study

Erika J. Thompson, Xifeng Wu, S. Colla, 2016, The Lancet. Oncology.

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, Blood advances.

Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

Xuelin Huang, Guillermo Garcia-Manero, Gautam Borthakur, 2016, British journal of haematology.

MYC protein expression is an important prognostic factor in acute myeloid leukemia

Z. Estrov, M. Andreeff, K. Bhalla, 2019, Leukemia & lymphoma.

cells and predicts poor clinical outcomes in AML leukemic stem/progenitor - 38 + Survivin is highly expressed in CD34

K. Coombes, G. Mills, Nianxiang Zhang, 2013 .

BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia

W. Pierceall, M. Konopleva, M. Andreeff, 2013, Molecular Cancer Therapeutics.

Companion Diagnostics and Biomarkers BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia

W. Pierceall, M. Konopleva, M. Andreeff, 2013 .

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

D. Berry, J. Issa, H. Kantarjian, 2010, Leukemia & lymphoma.

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

P. Vyas, B. Graves, M. Andreeff, 2015, Clinical Cancer Research.

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome

J. Issa, H. Kantarjian, G. Garcia-Manero, 2007, Cancer.

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial

M. Konopleva, Z. Estrov, D. Marin, 2017, JAMA oncology.

Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer

D. Berry, E. Feuer, W. Sauerbrei, 2018, Journal of the National Cancer Institute.

Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells

M. Konopleva, M. Andreeff, H. Kantarjian, 2016, Science Translational Medicine.

Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results

G. Garcia-Manero, Xuelin Huang, F. Ravandi, 2023, American journal of hematology.

Significance of recurrence of minimal residual disease detected by multi‐parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Cancer.

Clofarabine plus low‐dose cytarabine followed by clofarabine plus low‐dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2012, Cancer.

Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes.

P. Thall, C. Antonescu, R. Maki, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2008, Blood.

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, Clinical lymphoma, myeloma & leukemia.

Eradication of minimal residual disease in hairy cell leukemia.

H. Kantarjian, S. Verstovsek, Xuelin Huang, 2006, Blood.

Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs

W. Pierceall, M. Konopleva, M. Andreeff, 2015, PloS one.

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Blood.

New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2017, Applied immunohistochemistry & molecular morphology : AIMM.

Results of phase 2 randomized study of low‐dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

J. Issa, H. Kantarjian, G. Garcia-Manero, 2015, Cancer.

Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL)

Z. Estrov, M. Andreeff, H. Kantarjian, 2017 .

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

W. Chan, K. Fu, J. Vose, 2015, British journal of haematology.

Adjuvant high‐dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease

M. Ross, J. Gershenwald, Xuelin Huang, 2008, Cancer.

Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video‐endoscopic inguinal lymphadenectomy in patients with penile carcinoma

C. Wood, C. Dinney, S. Matin, 2013, BJU international.

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

Michael L. Wang, R. Davis, T. McDonnell, 2016, Science Signaling.

Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis

H. Koeppen, H. Kantarjian, G. Garcia-Manero, 2009, Cancer.

Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017, Blood.

Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021 .

Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.

C. Mullighan, M. Konopleva, H. Kantarjian, 2020, The Lancet. Haematology.

Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Cancer.

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, American journal of hematology.

The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017 .

Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

M. Konopleva, Z. Estrov, M. Andreeff, 2017, Cancer.

Phase 1 study of combinatorial sorafenib, G‐CSF, and plerixafor treatment in relapsed/refractory, FLT3‐ITD‐mutated acute myelogenous leukemia patients

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, American journal of hematology.

Final results of a phase 2 trial of clofarabine and low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, Cancer.

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, American journal of hematology.

Analysis of Longitudinal Data in the Presence of Informative Observational Times and a Dependent Terminal Event, with Application to Medical Cost Data

Lei Liu, John O'Quigley, Xuelin Huang, 2008, Biometrics.

Response‐adaptive randomization for clinical trials with adjustment for covariate imbalance

Jing Ning, Xuelin Huang, Xuelin Huang, 2010, Statistics in medicine.

A Parallel Phase I/II Clinical Trial Design for Combination Therapies

Xuelin Huang, Donald A Berry, D. Berry, 2007, Biometrics.

Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012

Oguzhan Alagoz, Harry J de Koning, Xuelin Huang, 2018, JAMA.

Maximum likelihood estimation of semiparametric mixture component models for competing risks data

Xuelin Huang, Sangbum Choi, 2014, Biometrics.

Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer

D. Berry, E. Feuer, R. Gray, 2018, Journal of the National Cancer Institute.

A Bayesian multi-stage cost-effectiveness design for animal studies in stroke research

Jing Ning, Chunyan Cai, Xuelin Huang, 2018, Statistical methods in medical research.

Efficient Two-Stage Designs and Proper Inference for Animal Studies

Jing Ning, Chunyan Cai, Xuelin Huang, 2018, Statistics in biosciences.

On the Landmark Survival Model for Dynamic Prediction of Event Occurrence Using Longitudinal Data

Liang Li, Yayuan Zhu, Xuelin Huang, 2018 .

Efficient semiparametric mixture inferences on cure rate models for competing risks

Xuelin Huang, J. Cormier, Sangbum Choi, 2015 .

A General Class of Semiparametric Transformation Frailty Models for Nonproportional Hazards Survival Data

Xuelin Huang, Sangbum Choi, 2012, Biometrics.

Analysis of multi‐stage treatments for recurrent diseases

Xuelin Huang, J. Ning, 2012, Statistics in medicine.

Joint analysis of correlated repeated measures and recurrent events processes in the presence of death, with application to a study on acquired immune deficiency syndrome

Xuelin Huang, Xuelin Huang, Lei Liu, 2009 .

A New Method for Quantitative Real-Time Polymerase Chain Reaction Data Analysis

Dejian Lai, Xuelin Huang, Xiayu Rao, 2013, J. Comput. Biol..

Response: Decitabine response with chromosome 7 abnormality in MDS, and decitabine optimal schedule

J. Issa, H. Kantarjian, Xuelin Huang, 2007 .

Increased expression of matrix metalloproteinase‐2 and tissue inhibitor of metalloproteinase‐2 is correlated with poor prognostic variables in patients with thymic epithelial tumors

L. McMahon, R. Wolfe, N. Janz, 2003, Cancer.

Personalized Targeted Mailing Increases Mammography Among Long-Term Noncompliant Medicare Beneficiaries: A Randomized Trial

L. McMahon, R. Wolfe, N. Janz, 2003, Medical care.

5‐Year mammography rates and associated factors for older women

L. McMahon, R. Wolfe, N. Janz, 2003, Cancer.

A conditional survival distribution-based method for censored data imputation: overcoming the hurdle in machine learning-based survival analysis

C. Flowers, Xuelin Huang, Ziyi Li, 2022, bioRxiv.

Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study

G. Garcia-Manero, Xuelin Huang, T. Kadia, 2022, Blood.

Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches

Jeroen J. van den Broek, E. Burnside, H. D. de Koning, 2018, Medical decision making : an international journal of the Society for Medical Decision Making.

Validation of tissue microarray technology in ovarian carcinoma

Xuelin Huang, Anais Malpica, Jinsong Liu, 2004, Modern Pathology.

Modified SuperCurve Method for Analysis of Reverse-Phase Protein Array Data

Li Zhang, Miao Sun, Dejian Lai, 2015, J. Comput. Biol..

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial

M. Konopleva, Z. Estrov, H. Kantarjian, 2018, Blood.

Frontline Therapy for Older Patients (pts) with Acute Myeloid Leukemia (AML): Clofarabine Plus Low-Dose Cytarabine Induction Followed by Prolonged Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2010 .

Reflecting on 20 years of breast cancer modeling in CISNET: Recommendations for future cancer systems modeling efforts

S. Plevritis, A. Trentham-Dietz, J. Mandelblatt, 2021, PLoS Comput. Biol..

A Bayesian response‐adaptive covariate‐balanced randomization design with application to a leukemia clinical trial

Ying Yuan, Suyu Liu, Xuelin Huang, 2011, Statistics in medicine.

Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.

H. Kantarjian, G. Garcia-Manero, Xuelin Huang, 2023, The Lancet. Haematology.

Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics

T. Haferlach, M. Andreeff, Xuelin Huang, 2023, Blood cancer journal.

A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS)

Hui Yang, Simona Colla, Xuelin Huang, 2016 .

Germinal centre‐like versus undifferentiated stromal immunophenotypes in follicular lymphoma

Xuelin Huang, L. Medeiros, Dan M. Jones, 2003, The Journal of pathology.

Personalized targeted mailing increases mammograms among long-term noncompliant Medicare beneficiaries: a randomized trial

L. McMahon, R. Wolfe, N. Janz, 2020 .

Bile duct complications of hepatic arterial infusion chemotherapy evaluated by helical CT

S. Curley, C. Charnsangavej, Xuelin Huang, 2005 .

Semiparametric Estimation of Longitudinal Medical Cost Trajectory

Chih-Hsien Wu, Jing Ning, Liang Li, 2018, Journal of the American Statistical Association.

Conditional Generative Adversarial Networks for Individualized Treatment Effect Estimation and Treatment Selection

Q. Ge, X. Huang, S. Fang, 2020, Frontiers in Genetics.

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

M. Andreeff, G. Garcia-Manero, J. Cortes, 2023, Journal of Hematology & Oncology.

Using short‐term response information to facilitate adaptive randomization for survival clinical trials

Jing Ning, Xuelin Huang, Donald A Berry, 2009, Statistics in medicine.

Optimization of multi‐stage dynamic treatment regimes utilizing accumulated data

Peter F Thall, Lu Wang, Xuelin Huang, 2015, Statistics in medicine.

Landmark linear transformation model for dynamic prediction with application to a longitudinal cohort study of chronic disease

Liang Li, Yayuan Zhu, Xuelin Huang, 2018, Journal of the Royal Statistical Society. Series C, Applied statistics.

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

M. Konopleva, M. Andreeff, H. Kantarjian, 2023, Blood advances.

Updated results from phase II study of guadecitabine for patients with higher risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2017 .

Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a

F. Bertucci, D. Birnbaum, W. Woodward, 2015, Breast Cancer Research and Treatment.

Pharmacodynamic Biomarkers in the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

L. Vassilev, M. Konopleva, M. Andreeff, 2011 .

A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017 .

Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

Semiparametric accelerated intensity models for correlated recurrent and terminal events

Xuelin Huang, J. Ning, Sangbum Choi, 2017 .

A two‐stage approach for dynamic prediction of time‐to‐event distributions

Jing Ning, Fangrong Yan, Ziding Feng, 2016, Statistics in medicine.

A prognostic score for patients with lower risk myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, Xuelin Huang, 2008, Leukemia.

Dynamic prediction of disease progression for leukemia patients by functional principal component analysis of longitudinal expression levels of an oncogene

Xiao Lin, Fangrong Yan, Xuelin Huang, 2017 .

Ruxolitinib for symptom control in patients with Chronic Lymphocytic leukemia: A Phase II Trial

C. Cleeland, Z. Estrov, D. Harris, 2017, The Lancet. Haematology.

Contributions of screening, early-stage treatment, and metastatic treatment to breast cancer mortality reduction by molecular subtype in U.S. women, 2000-2017.

Jennifer L. Caswell-Jin, D. Berry, S. Plevritis, 2022, Journal of Clinical Oncology.

Bile duct complications of hepatic arterial infusion chemotherapy evaluated by helical CT.

S. Curley, C. Charnsangavej, Xuelin Huang, 2005, Clinical radiology.

CASi: A multi-timepoint scRNAseq data analysis framework

Xuelin Huang, Ziyi Li, Yizhuo Wang, 2023, bioRxiv.

Prediction of Ovarian Cancer Response to Therapy Based on Deep Learning Analysis of Histopathology Images

J. Weinstein, B. Broom, Yuexin Liu, 2023, Cancers.

MASH: MEDIATION ANALYSIS OF SURVIVAL OUTCOME AND HIGH-DIMENSIONAL OMICS MEDIATORS WITH APPLICATION TO COMPLEX DISEASES

Xuelin Huang, Sunyi Chi, Ziyi Li, 2023, bioRxiv.

The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients

H. Kantarjian, Xuelin Huang, M. Keating, 2012 .

Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients

H. Kantarjian, Xuelin Huang, M. Keating, 2013 .

Dynamic prediction of time to a clinical event with sparse and irregularly measured longitudinal biomarkers

Liang Li, Xuelin Huang, Yayuan Zhu, 2020, Biometrical journal. Biometrische Zeitschrift.

Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Leukemia.

Empirical Comparison of the Breslow Estimator and the Kalbfleisch Prentice Estimator for Survival Functions

Xuelin Huang, J. Ning, Fang Xia, 2018, Journal of biometrics & biostatistics.

A note on the Breslow survival estimator

Robert L. Strawderman, Xuelin Huang, R. Strawderman, 2006 .

Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML

M. Andreeff, Xuelin Huang, S. Kornblau, 2013, Apoptosis.

Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

K. Baggerly, E. Estey, M. Konopleva, 2014, Clinical Cancer Research.

A signature enrichment design with Bayesian adaptive randomization

S. George, Xuelin Huang, J. Ning, 2020, Journal of applied statistics.

Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy.

H. Kantarjian, J. Cortes, Xuelin Huang, 2014, Clinical Lymphoma, Myeloma & Leukemia.

On the time‐varying predictive performance of longitudinal biomarkers: Measure and estimation

Xuelin Huang, J. Ning, Jing Zhang, 2021, Statistics in medicine.

Quantile residual lifetime regression with functional principal component analysis of longitudinal data for dynamic prediction

Tao Lu, Xiao Lin, Fangrong Yan, 2019, Statistical methods in medical research.

Estimation of the distribution of longitudinal biomarker trajectories prior to disease progression

Jing Ning, Liang Li, Lei Liu, 2019, Statistics in medicine.

Mean residual life regression with functional principal component analysis on longitudinal data for dynamic prediction

Tao Lu, Xiao Lin, Fangrong Yan, 2018, Biometrics.

Functional principal components analysis on moving time windows of longitudinal data: dynamic prediction of times to event

Xiao Lin, Ruosha Li, Fangrong Yan, 2018 .

Quantile residual life regression with longitudinal biomarker measurements for dynamic prediction

Xuelin Huang, Ruosha Li, Jorge E. Cortes, 2016 .

Relative RATIO Of BCR-ABL1 Transcript Clearance Improves The Prognostic VALUE Of Single PCR Assessment At The 3 and 6 Month Time Points In Patients With Chronic Myeloid Leukemia In Chronic PHASE Treated In The Dasision Study

H. Kantarjian, J. Cortes, Xuelin Huang, 2013 .

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Blood.

Optimization of multi‐stage dynamic treatment regimes utilizing accumulated data

P. Thall, Xuelin Huang, Lu Wang, 2015, Statistics in medicine.

Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2016 .

Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016, British journal of haematology.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2008, Blood.

Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.

C. Flowers, Linghua Wang, Xuelin Huang, 2022, The Lancet. Oncology.

Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.

Michael L. Wang, Y. Oki, P. Mclaughlin, 2015, Clinical lymphoma, myeloma & leukemia.

Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

S118: A CHEMOTHERAPY-FREE COMBINATION OF PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SUBGROUP ANALYSIS FROM A PHASE II STUDY

M. Konopleva, Xuelin Huang, T. Kadia, 2023, HemaSphere.

A phase II trial of ponatinib and blinatumomab in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

H. Kantarjian, Xuelin Huang, T. Kadia, 2023, Journal of Clinical Oncology.

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, M. Andreeff, 2011 .

Maximum likelihood estimation of semiparametric mixture component models for competing risks data

Xuelin Huang, Sangbum Choi, 2014, Biometrics.

Semiparametric accelerated failure time cure rate mixture models with competing risks

Liang Zhu, Xuelin Huang, Sangbum Choi, 2018, Statistics in medicine.

Regression Survival Analysis with an Assumed Copula for Dependent Censoring: A Sensitivity Analysis Approach

Xuelin Huang, N. Zhang, 2008, Biometrics.

A class of semiparametric transformation models for survival data with a cured proportion

Xuelin Huang, Yi-Hau Chen, Sangbum Choi, 2013, Lifetime Data Analysis.

p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.

M. Konopleva, M. Andreeff, E. Shpall, 2011, Blood.

Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML.

K. Coombes, G. Mills, Nianxiang Zhang, 2012, Blood.

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

D. Berry, J. Issa, H. Kantarjian, 2010, Leukemia & lymphoma.

Chemotherapy-Free Combination of Blinatumomab and Ponatinib in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updates from a Phase II Trial

H. Kantarjian, Xuelin Huang, T. Kadia, 2023, Blood.

S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL

G. Garcia-Manero, Xuelin Huang, T. Kadia, 2023, HemaSphere.

Design and inference for 3‐stage bioequivalence testing with serial sampling data

Xuelin Huang, Jun-Lin Liu, Fangrong Yan, 2018, Pharmaceutical statistics.

Evaluation of soluble KIT (sKIT) as a potential surrogate marker for TTP in sunitinib malate (SU)-treated patients (pts) with advanced GIST

G. Demetri, J. Verweij, P. Casali, 2007 .